問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Cheng Hsin General Hospital (在職)

Division of Cardiovascular Diseases

更新時間：2023-09-19

殷偉賢
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

4Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

殷偉賢

List

19Cases

2023-03-01 - 2027-02-28

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting16Sites

2013-02-15 - 2018-09-30

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

  • Condition/Disease

    Acute Coronary Syndrome

  • Test Drug

    SAR236553/REGN727

Participate Sites
15Sites

Terminated15Sites

蔡惟全
National Taiwan University Hospital

Division of Cardiovascular Diseases

2007-05-01 - 2008-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2017-01-01 - 2020-06-30

Phase III

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction

  • Condition/Disease

    Chronic Heart Failure

  • Test Drug

    Forxiga

Participate Sites
15Sites

Terminated13Sites

江晨恩
Taipei Veterans General Hospital

Division of Cardiovascular Diseases

謝宜璋
Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

2018-11-19 - 2022-12-01

Phase III

An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

  • Condition/Disease

    Heart Failure With Preserved Ejection Fraction (HFpEF)

  • Test Drug

    dapagliflozin film-coated tablets

Participate Sites
15Sites

Recruiting13Sites

江晨恩
Taipei Veterans General Hospital

Division of Cardiovascular Diseases

2017-02-01 - 2019-05-09

Phase III

Evaluation of the safety and efficacy of an edoxaban-based compared to a vitamin K antagonist-based antithrombotic regimen following successful percutaneous coronary intervention (PCI) with stent placement. (EdoxabaN Treatment versus VKA in patients with AF undergoing PCI ( ENTRUST-AF PCI)

  • Condition/Disease

    Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) With Stent Placement

  • Test Drug

    Edoxaban (DU-176b)

Participate Sites
13Sites

Terminated11Sites

江晨恩
Taipei Veterans General Hospital

Division of Cardiovascular Diseases

2015-08-01 - 2018-12-31

Phase II

Antihypertensive effect of different doses of Rostafuroxin in comparison with Losartan, assessed by office and ambulatory blood pressure monitoring in a hypertensive population selected according to a specific genetic profile.

  • Condition/Disease

    hypertension

  • Test Drug

    Rostafuroxin

Participate Sites
14Sites

Terminated12Sites

2006-12-18 - 2010-09-07

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Terminated13Sites

2015-06-01 - 2016-12-31

Phase III

A Phase III Prospective, Randomized, Double Blind, Active Controlled, Multicenter, Parallel Group Study to Assess the Safety and Effectiveness of Once Daily PMR Compared to Twice Daily Pletaal® in Patients with Intermittent Claudication

  • Condition/Disease

    Intermittent Claudication

  • Test Drug

    PMR

Participate Sites
6Sites

Terminated6Sites

2010-04-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Study ended7Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB